Insider · CIK 0001813367
Vijay Chandru
director
Files at LTRN (Lantern Pharma Inc.). First filing -, latest -.
Track record
Not enough history
Fewer than three past buys with six months of prices.
Median 6-month excess
-
after past buys, n = 0
Hit rate
-
past buys that beat the index over 6 months
Open-market trades
0 / 0
$0 bought, $0 sold
Signals
This insider’s open-market buys and sells, scored.
No scored open-market trades yet.
Transactions
Every row this insider has filed, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Jan 9, 2026 | LTRN Lantern Pharma Inc. | AGrant or award Stock Option (Right to Buy)derivative | +25,000 | $0.00 | $0 | 25,000 | Jan 13, 2026 |
| Jan 9, 2026 | LTRN Lantern Pharma Inc. | AGrant or award Stock Option (Right to Buy)derivative | +17,307 | $0.00 | $0 | 17,307 | Jan 13, 2026 |
| Jun 15, 2020 | LTRN Lantern Pharma Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -9,135 | $0.00 | $0 | 0 | Sep 23, 2025 |
| Jun 15, 2020 | LTRN Lantern Pharma Inc. | AGrant or award Stock Option (Right to Buy)derivative | +9,135 | $0.00 | $0 | 9,135 | Sep 23, 2025 |
| Nov 4, 2021 | LTRN Lantern Pharma Inc. | DDisposition to issuer Stock Option (Right to Buy)derivative | -3,200 | $0.00 | $0 | 0 | Sep 23, 2025 |
| Nov 4, 2021 | LTRN Lantern Pharma Inc. | AGrant or award Stock Option (Right to Buy)derivative | +3,200 | $0.00 | $0 | 3,200 | Sep 23, 2025 |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.